The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform . "The addition of this new patent continues to strengthen our IP position around core cell therapy components and helps protect our leading position in the regenerative medicine field," said , Ph.D., President and Chief Executive Officer.
http://ift.tt/1DkyX6b
http://ift.tt/1DkyX6b
No comments:
Post a Comment